Zacks: Brokerages Expect Thermo Fisher Scientific Inc. (NYSE:TMO) to Post $4.93 Earnings Per Share

Wall Street analysts expect Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) to post earnings of $4.93 per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Thermo Fisher Scientific’s earnings, with the highest EPS estimate coming in at $5.19 and the lowest estimate coming in at $4.72. Thermo Fisher Scientific reported earnings of $5.60 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 12%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Thermo Fisher Scientific will report full-year earnings of $22.70 per share for the current year, with EPS estimates ranging from $22.65 to $22.80. For the next fiscal year, analysts anticipate that the business will report earnings of $24.42 per share, with EPS estimates ranging from $24.00 to $25.30. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical research company reported $7.25 earnings per share for the quarter, beating the consensus estimate of $6.20 by $1.05. The company had revenue of $11.82 billion during the quarter, compared to analysts’ expectations of $10.66 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. Thermo Fisher Scientific’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter last year, the company earned $7.21 EPS.

Several equities research analysts have issued reports on the stock. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $605.00 to $525.00 in a research report on Monday, April 25th. BTIG Research restated a “buy” rating and set a $718.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, February 3rd. Barclays assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 26th. They set an “overweight” rating and a $700.00 target price on the stock. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $609.00 target price on the stock. in a research note on Monday, January 24th. Finally, StockNews.com started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $647.00.

Thermo Fisher Scientific stock traded up $0.06 during midday trading on Monday, reaching $555.21. 1,126,511 shares of the company’s stock were exchanged, compared to its average volume of 1,624,917. Thermo Fisher Scientific has a 52 week low of $438.72 and a 52 week high of $672.34. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.10 and a current ratio of 1.56. The firm has a market cap of $217.34 billion, a price-to-earnings ratio of 28.95, a P/E/G ratio of 1.87 and a beta of 0.83. The stock’s 50-day simple moving average is $565.30 and its 200 day simple moving average is $589.70.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Stockholders of record on Wednesday, June 15th will be paid a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 0.22%. The ex-dividend date is Tuesday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.26%.

In other news, CEO Marc N. Casper sold 2,181 shares of the firm’s stock in a transaction dated Wednesday, May 4th. The shares were sold at an average price of $562.46, for a total value of $1,226,725.26. Following the sale, the chief executive officer now directly owns 183,373 shares in the company, valued at approximately $103,139,977.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $545.60, for a total transaction of $5,456,000.00. Following the completion of the transaction, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at $100,048,308.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,381 shares of company stock worth $6,791,597. Company insiders own 0.43% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. EagleClaw Capital Managment LLC increased its stake in Thermo Fisher Scientific by 12.0% during the third quarter. EagleClaw Capital Managment LLC now owns 8,110 shares of the medical research company’s stock worth $4,634,000 after purchasing an additional 870 shares during the period. BerganKDV Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 24.5% in the third quarter. BerganKDV Wealth Management LLC now owns 127 shares of the medical research company’s stock valued at $73,000 after purchasing an additional 25 shares in the last quarter. Impax Asset Management Group plc lifted its stake in Thermo Fisher Scientific by 0.6% in the third quarter. Impax Asset Management Group plc now owns 467,330 shares of the medical research company’s stock valued at $267,000,000 after buying an additional 2,949 shares during the last quarter. Bristol Gate Capital Partners Inc. raised its stake in shares of Thermo Fisher Scientific by 2.7% during the third quarter. Bristol Gate Capital Partners Inc. now owns 175,780 shares of the medical research company’s stock worth $100,428,000 after purchasing an additional 4,656 shares during the last quarter. Finally, TrinityPoint Wealth LLC raised its position in Thermo Fisher Scientific by 9.4% in the third quarter. TrinityPoint Wealth LLC now owns 584 shares of the medical research company’s stock worth $334,000 after acquiring an additional 50 shares in the last quarter. 87.48% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.